AbbVie announced positive Phase 2 results for zumilokibart, a monoclonal antibody targeting IL-13, in adults with moderate-to-severe atopic dermatitis. All dose regimens met the primary endpoint with significant improvements in skin severity and itch compared to placebo at 16 weeks. The mid-dose regimen was chosen for Phase 3 development to further assess efficacy, safety, and dosing convenience. This advancement offers hope for a more effective, long-term treatment option for patients with atopic dermatitis.
AbbVie shares trade at USD 264.00 on Pluang as of Sep 30, 2026 12:12 WIB, close to their 52-week high of USD 266.40. Despite the positive Phase 2 results for zumilokibart announced in this news, the stock shows a slight 0.90% decline in the last day. Pluang investors currently favor buying AbbVie with 74% of order activity on the platform, reflecting ongoing interest in the health sector giant.
AbbVie presented 60 abstracts at the 2026 European Academy of Dermatology and Venereology Congress, showcasing new data on its dermatology portfolio including approved drugs risankizumab (SKYRIZI) and upadacitinib (RINVOQ), as well as investigational...
AbbVie has formed a new collaboration with Valkai to enhance its artificial intelligence (AI) capabilities in clinical development. This partnership aims to improve efficiency in clinical research, accelerate insight generation, and reduce drug devel...
AbbVie announced FDA approval of JUVMO™ (tavapadon), the first selective D1/D5 receptor agonist for treating adults with Parkinson's disease. JUVMO offers a novel approach to motor symptom control, improving daily functioning and increasing 'on' time...
AbbVie and Johnson & Johnson are both strong dividend stocks trading near their 52-week highs, but they differ significantly in risk and growth. AbbVie shows faster revenue growth and a higher dividend yield, driven by its immunology drugs, but faces...
